SOLE: Study Of Letrozole Extension in post-menopausal women with breast cancer
ISRCTN | ISRCTN43286545 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN43286545 |
EudraCT/CTIS number | 2007-001370-88 |
ClinicalTrials.gov number | NCT00553410 |
Secondary identifying numbers | IBCSG 35-07/BIG 1-07 |
- Submission date
- 02/09/2009
- Registration date
- 03/11/2009
- Last edited
- 27/07/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Contact information
Scientific
Professor of Surgical Oncology
University of Dundee
Ninewells Hospital & Medical School
Dundee
DD1 9SY
United Kingdom
Phone | +44 (0)1382 633936 |
---|---|
a.m.thompson@dundee.ac.uk |
Study information
Study design | Randomised controlled phase III trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for post-menopausal women with hormone-receptor positive, node positive early stage breast cancer |
Study acronym | SOLE |
Study objectives | In 2006, the standard duration of adjuvant endocrine therapy for breast cancer (either selective estrogen receptor modulators [SERMs] or aromatase inhibitor [AI]) is five years. Patients who receive extended adjuvant letrozole for five years following approximately five years of tamoxifen obtain further benefit compared with the five years of tamoxifen alone. Similarly, benefit has been demonstrated for switching from tamoxifen to an AI after 2 to 3 years of tamoxifen to complete five years of endocrine therapy, as well as initiating therapy with AI following surgery and administering the AI for five years. Questions remain about the optimal duration and best schedule of AIs in the extended adjuvant setting. This trial tests the hypothesis that introducing 3-month treatment-free intervals during the course of five years of extended adjuvant letrozole will improve disease-free survival. This hypothesis is based on the theoretical principle that letrozole withdrawal for 3 months will permit some estrogenic stimulation which makes residual resistant disease susceptible to letrozole reintroduction. |
Ethics approval(s) | Not provided at time of registration |
Health condition(s) or problem(s) studied | Breast cancer |
Intervention | Arm A - Continuous letrozole 2.5 mg daily for 5 years Arm B - Intermittent letrozole 2.5 mg daily for first 9 months of years 1 through 4, followed by 12 months in year 5 |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase III |
Drug / device / biological / vaccine name(s) | Letrozole |
Primary outcome measure | Disease-free survival (DFS) is defined as the time from randomisation to local (including invasive recurrence restricted to the breast after breast conserving treatment), regional or distant relapse, contralateral breast cancer, appearance of a second (non-breast) malignancy, or death from any cause, whichever occurs first. Appearance of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) either in the ipsilateral or in the contralateral breast will not be considered as an event for DFS. Event driven analyses - final analysis requires 647 events, interim analysis at 259 and 453 events. |
Secondary outcome measures | 1. Overall survival (OS) is defined as the time from randomisation to death from any cause 2. Distant disease-free survival (DDFS) is defined as the time from randomisation to any recurrent or metastatic disease in distant sites (i.e., other than the local mastectomy scar/chest wall/skin, the ipsilateral breast in case of breast conservation, or the ipsilateral axilla and internal mammary lymph nodes), second (non-breast) malignancy, or death from any cause, whichever occurs first 3. Breast cancer free interval (BCFI) is defined as the time from randomisation to local (including recurrence restricted to the breast after breast conserving treatment), regional, or distant relapse, or contralateral breast cancer. In calculating BCFI, second (non-breast) malignancies are ignored and deaths without cancer event are censored at the time of death as a competing event. Appearance of DCIS or LCIS either in the ipsilateral or in the contralateral breast is not considered a BCFI event, but should be recorded on the Follow-up Form (E) 4. Sites of first DFS failure 5. Second (non-breast) malignancies 6. Deaths without prior cancer event 7. Adverse events Event driven analyses - final analysis requires 647 events, interim analysis at 259 and 453 events. |
Overall study start date | 01/11/2007 |
Completion date | 31/12/2018 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Other |
Sex | Female |
Target number of participants | UK: 300; total International sample including UK: 4800; European economic area: 3500 |
Total final enrolment | 4884 |
Key inclusion criteria | 1. Patients must be post-menopausal; definitive confirmation of post-menopausal status is required 2. Patients must be accessible for follow-up 3. At diagnosis, patients must have had operable, non-inflammatory breast cancer 4. Patients must be clinically disease-free at randomisation 5. Patients must have had steroid hormone receptor positive tumours (oestrogen receptor [ER] and/or progesterone receptor [PgR]), determined by immunohistochemistry, after primary surgery and before commencement of prior endocrine therapy 6. Following primary surgery, eligible patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes, but not supraclavicular nodes 7. There must have been no evidence of recurrent disease or distant metastatic disease at any time prior to randomisation 8. Patients must have had proper local treatment including surgery with or without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease 9. Patients must have clinically adequate hepatic function 10. Patients must have completed 4 to 6 years of prior adjuvant endocrine therapy with SERMs, AI or a sequential combination of both. When calculating 4 - 6 years, neoadjuvant endocrine therapy should not be included. 11. Patients must have stopped prior endocrine SERM/AI therapy, and must be randomized within 12 months (1 year) of the last dose of prior endocrine SERM/AI therapy 12. Patients may have received any type of prior adjuvant therapy, including but not limited to neoadjuvant chemotherapy, neoadjuvant endocrine therapy, adjuvant chemotherapy, trastuzumab, ovarian ablation, GnRH analogues, lapatinib 13. Patients must have stopped hormone replacement therapy (HRT), bisphosphonates (except for treatment of bone loss), or any investigational agent at randomisation 14. Pathology material from the primary tumour must be available for submission for central review as part of the quality control measures for this protocol 15. Written informed consent (IC) must be signed and dated by the patient and the investigator prior to randomisation 16. Written consent to pathology material submission, indicating the patient has been informed of and agrees to tissue material use, transfer and handling, must be signed and dated by the patient and the investigator prior to randomisation 17. Females, no defined age limits |
Key exclusion criteria | 1. Patients who have had bilateral breast cancer 2. Patients who have had a bone fracture due to osteoporosis at any time during the 4-6 years of prior endocrine SERM/AI therapy 3. Patients who have had any previous or concomitant malignancy EXCEPT adequately treated: basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, contra- or ipsilateral in situ breast carcinoma 4. Patients who have had any other non-malignant systemic diseases (cardiovascular, renal, lung, etc.) that would prevent prolonged follow-up 5. Patients with psychiatric, addictive, or any disorder which compromises compliance with protocol requirements |
Date of first enrolment | 01/11/2007 |
Date of final enrolment | 08/10/2012 |
Locations
Countries of recruitment
- Australia
- Belgium
- Chile
- Denmark
- Germany
- Hungary
- Italy
- New Zealand
- Peru
- Scotland
- South Africa
- Sweden
- Switzerland
- United Kingdom
Study participating centre
DD1 9SY
United Kingdom
Sponsor information
Research organisation
c/o Aron Goldhirsch
Via Ripamonti 435
Milano
20141
Italy
Website | http://www.ieo.it/inglese/index.asp |
---|---|
https://ror.org/02vr0ne26 |
Funders
Funder type
Research organisation
No information available
Results and Publications
Intention to publish date | 31/12/2019 |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Data sharing statement to be made available at a later date |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan | The data sharing plans for the study are currently unknown and will be made available at a later date |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Basic results | 10/09/2019 | No | No | ||
Results article | results | 01/01/2018 | 10/09/2019 | Yes | No |
Plain English results | 27/07/2022 | No | Yes |
Editorial Notes
27/07/2022: Cancer Research UK plain English results summary link and total final enrolment added.
10/09/2019: ClinicalTrials.gov number and EudraCT number added. Publication reference added. Added ClinicalTrials.gov link to basic results (scientific).
22/07/2019: IPD sharing statement added.
19/07/2019: The following changes were made to the trial record:
1. The overall trial end date was changed from 01/11/2021 to 31/12/2018.
2. The recruitment end date and intention to publish date were added.